Literature DB >> 16169302

Plasma fibrinogen in ulcerative colitis: the effect of disease activity and nicotine therapy in a randomised controlled trial.

J R Ingram1, J Rhodes, P W Collins, G T Williams, R G Newcombe, G A O Thomas.   

Abstract

BACKGROUND: Smoking increases plasma fibrinogen and cardiovascular risk whereas transdermal nicotine may not. Fibrinogen is an acute phase protein and may reflect disease activity in ulcerative colitis. AIMS: To examine the effect of topical nicotine on plasma fibrinogen and any relationship between fibrinogen and ulcerative colitis disease activity. PATIENTS: Forty-eight non-smokers with moderately active ulcerative colitis.
METHODS: Patients were randomised to 6 mg nicotine enema or placebo for 6 weeks, followed by open nicotine therapy for 4 weeks. Plasma fibrinogen was measured at baseline and after 6 and 10 weeks; at each assessment sigmoidoscopy with a rectal biopsy was performed. RESULTS.: At 6 weeks median plasma fibrinogen was 3.30 g/l on nicotine compared to 3.05 g/l on placebo, P = 0.90 when adjusted for baseline values. There was a correlation between fibrinogen and the UC disease activity index (UCDAI) at weeks 0 and 10, P = 0.036 and 0.033, respectively, and between fibrinogen and sigmoidoscopic grade at each assessment, P = 0.014, 0.021 and 0.034. Changes in fibrinogen did not correlate with changes in disease severity.
CONCLUSIONS: There was no significant effect of nicotine enemas, in either direction, on plasma fibrinogen-this was raised in moderately active UC and correlated with the sigmoidoscopic grade of colitis and the UCDAI; however, fibrinogen was not sufficiently sensitive to be of practical clinical value.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169302     DOI: 10.1016/j.dld.2005.05.010

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  2 in total

1.  Nicotinic acetylcholine receptor expression and susceptibility to cholinergic immunomodulation in human monocytes of smoking individuals.

Authors:  Esmerij P van der Zanden; Francisca W Hilbers; Caroline Verseijden; Rene M van den Wijngaard; Mike Skynner; Kevin Lee; Luis Ulloa; Guy E Boeckxstaens; Wouter J de Jonge
Journal:  Neuroimmunomodulation       Date:  2012-03-21       Impact factor: 2.492

Review 2.  Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease.

Authors:  Ana Cristina Alves de Almeida; Felipe Meira de-Faria; Ricardo José Dunder; Luis Paulo Bognoni Manzo; Alba Regina Monteiro Souza-Brito; Anderson Luiz-Ferreira
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-09       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.